MDCX

Medicus Pharma Ltd. (MDCX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Medicus Pharma Ltd. is a clinical-stage, multi-strategy biotechnology company focused on advancing therapeutic assets, primarily its SkinJect microneedle platform for skin cancer and the acquired Antev Limited's Teverelix program for prostate cancer and urinary retention. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Note: The company reported no revenue for the periods presented. Total debt increased significantly due to new secured promissory notes issued in May 2026.

Material Changes vs. Prior Period

• Operating Expenses: Increased by 90% year-over-year for the six-month period (from $11.1M to $20.1M). This was driven by a 121% increase in R&D expenses (due to the integration of Antev's Teverelix program) and a 62% increase in G&A expenses (due to headcount growth and stock-based compensation).
• Net Loss: Net loss for the six months ended June 30, 2026, was $20.7M, compared to $11.3M in the same period in 2025.
• Debt Structure: The company extinguished a $2.3M Yorkville debenture and issued two new secured promissory notes (Note A and Note B) totaling $22.9M principal to Streeterville Capital, LLC. $10M of Note B proceeds are held in a restricted cash account.
• Equity Issuance: The company issued approximately 28.2M shares under its At-The-Market (ATM) program and 5.3M shares under its Standby Equity Purchase Agreement (SEPA), raising significant capital to fund operations.

Outlook, Risks, and Management Commentary

• Going Concern: Management explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern within one year due to a history of losses and the need for additional financing.
• Clinical Progress:
  • SkinJect: Received FDA "Study May Proceed" letter for a registrational Phase 2b study in Gorlin Syndrome. Reported positive dose-response data in Phase 2 SKNJCT-003 study (64% clinical clearance in 200ug cohort).
  • Teverelix: Received FDA feedback and IRB approval for an optimized Phase 2 study for Acute Urinary Retention (AUR). Received IND authorization in the UAE for a Phase 2a study in endometriosis.
• Listing Compliance: The company received a Nasdaq deficiency notice regarding the minimum bid price requirement (stock traded below $1.00 for 30 consecutive days). It has 180 days (until October 19, 2026) to regain compliance.
• Capital Resources: The company relies on its ATM program (up-sized to $50M), SEPA (approx. $2.5M remaining capacity), and potential future equity/debt offerings to fund operations.

Investor Verification Checklist

• Restricted Cash: Verify the terms of the $10M restricted cash account held for Note B and the conditions under which it can be released.
• Debt Covenants: Review the specific trigger events and redemption rights in the Streeterville Capital promissory notes, including the 20% penalty for missed redemptions and potential interest rate hikes to 18% upon default.
• Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the October 19, 2026 deadline.
• Going Concern Status: Assess the timeline for the next round of financing given the explicit "substantial doubt" disclosure and the burn rate of approximately $16M in operating cash over six months.
• Antev Integration: Verify the progress of the Teverelix clinical trials and the potential for contingent consideration payments based on milestone achievements.